Still looks cheap15 Oct 2009 00:59
I don't normally touch this type of company, but having done a bit of research it does look worth a punt. They have no debt, enough cash to keep them going for a while and seem to get a fair bit of money from charitable organizations for research. Missed all the early gains and got in at just over 27p. However, with a company valuation of £25 million and the possibility - I know it's still early days - of producing a drug that is the world leader in the fight against Parkinson's, it looks very cheap.